Project Title: Terminal Sterilization of a Heat Unstable Molecule: Succinylcholine Chloride (SCC)

Subtitle: The Challenge of Converting SCC Sterile Injectable Products from Aseptic to Terminal Sterilization Processes

- Date: March 2026
- Consultant: Jean-Marie Geoffroy, PhD

White Paper: *Succinylcholine Chloride (SCC) Stability: Why Aseptic Processing Trumps Terminal Sterilization* or *The Sterilization Paradox: Impact of Heat on Succinylmonocholine (SMC) Formation*

Subject: Technical Justification for Aseptic Processing over Terminal Sterilization

The following is a theoretical analysis from readily available public data demonstrating the challenges of terminally sterilizing a heat-sensitive molecule. To date, no terminally sterilized injectable products of succinylcholine chloride have been commercialized; however, the possibility remains that this problem could be cracked with a proper approach.

I. Executive Summary (STAR Format)

- **Situation:** Succinylcholine Chloride (SCC), an essential neuromuscular blocking agent, requires a Sterility Assurance Level (SAL) of per FDA/EMA mandates. However, its molecular structure—a di-choline ester—is highly sensitive to hydrolytic degradation.

- **Task:** Determine the feasibility of a standard Terminal Sterilization (TS) cycle (for 15 minutes) while maintaining potency and impurity levels within **USP Monograph limits (SMC 2.0%)**.

- **Action:** Conducted kinetic simulations in Type I glass vials to assess SCC stability and Succinylmonocholine (SMC) formation at an F_o of 16.72. Evaluated standard buffering vs. advanced stabilization and analyzed the impact of cumulative thermal stress.

- **Results:** At F_o of 16.72, the SCC concentration is predicted to drop significantly, and SMC levels to rise to levels incompatible with USP standards. Even sub-lethal cycles ($F_o \sim 8$) provide an insufficient margin for commercial, robust manufacturing.

- **Conclusion:** Terminal sterilization is technically non-viable for aqueous solutions of SCC. Aseptic processing is the only method that preserves the Critical Quality Attributes (CQAs) of the drug product.

II. Background Chemistry & Degradation Kinetics

SCC is inherently unstable in aqueous environments. The degradation follows a pseudo-first-order hydrolytic pathway where the parent molecule (SCC) is cleaved into **Succinylmonocholine (SMC)** and eventually into Succinic Acid and Choline (Figure 1).



Figure 1. Chemical structures of Succinylcholine Chloride and Its Impurities

1. Kinetic Parameters

- **Reaction Order:** Pseudo-first-order.
- **Activation Energy (E_a):** Approximately 75-92 kJ/mol.
- **pH Stability:** The peak stability resides in a narrow band of **pH 3.0 to 4.5**.
- **Buffer Sensitivity:** Common buffers like **Citrates and Phosphates** accelerate degradation at high temperatures via **General Base Catalysis**, where the buffer ions facilitate the nucleophilic attack on the ester bond.

III. Simulation Visuals: TS Profile ($F_o = 16.72$)

The following simulation data represents a typical product load in Type I glass vials during a standard 121ºC / 15-minute cycle.

1. Impurity Generation (SMC)

As the autoclave temperature rises (red dashed line), the predicted rate of SMC formation (blue line) increases exponentially (Figure 2). Even before reaching the 15-minute dwell time, the impurity level begins to climb, peaking as the system slowly cools.



Figure 2. ***Increase in SMC concentration as a function of Terminal Sterilization Time and Temperature***



Figure 3. ***Sensitivity Analysis of Predicted Decreases in SCC and Increases in SMC As a Function of Terminal Sterilization Process Time and Temperature Assuming Three Different Activation Energies (E_a)***

2. Potency Loss (SCC)

The parent drug concentration shows a mirrored decline (Figure 3). The "thermal lag" inherent in glass vials means the drug is exposed to degradative temperatures longer than the nominal cycle time, resulting in significant potency loss.

IV. Comparative Stability Data Table

Based on the simulations provided, the impact of various targets on the USP limit for SMC is summarized below:

Sterilization Method	Target	Resulting SMC (%)	USP Status (Limit: 2.0%)
Aseptic Filtration	0.00	< 0.1%	**Pass**
Bioburden-Based TS	8.00	2.8% – 3.2%	**Fail**
Standard Overkill	**16.72**	**> 5.0%**	**Fail**
Double-Sterilization	~33.0	> 10.0%	**Fail**

V. Regulatory Logic & Conclusion

1. The "Double-Sterilization" Risk

Regulatory robustness requires that a manufacturing process withstands minor deviations, such as a cycle interruption. In an SCC process, the degradation is **strictly cumulative**. An F_o of 16.72 already pushes the product out of specification; a second cycle would result in total batch loss. This lack of "thermal margin" makes TS a high-risk commercial strategy.

2. Non-Viability of Radiation

Alternative methods such as Gamma or E-beam are also unsuitable. They trigger **water radiolysis**, creating free radicals that degrade the ester bond as aggressively as heat, while also causing glass solarization and pH shifts.

3. Conclusions

The literature and simulation data converge on two primary points:

- **Predictive analysis suggests that it is not possible to terminally sterilize SCC** in its current aqueous form without exceeding the USP limit for SMC.
- **Reformulation is not a viable alternative:** While non-aqueous solvents could stabilize the molecule, they would require extensive new clinical safety and toxicological studies, effectively changing the drug's safety profile.

Recommendation: Consistent with **CPMP/QWP/054/98 and based on this model**, aseptic processing is the only technically and defensible manufacturing method for Succinylcholine Chloride Injections.

VI. Verified References & Technical Citations

1. Chemical Kinetics and Degradation Pathways

- **Whittaker, M. (1980).** "The Hydrolysis of Succinylcholine." *Anaesthesia*, 35(7).
  - *Key Input:* Establishes the two-step hydrolysis of SCC to SMC and then to succinic acid and choline.
- **Naguib, M., et al. (2004).** "Succinylcholine: New Insights into its Chemical and Biological Properties." *Anesthesiology*.
  - *Key Input:* Confirms the pseudo-first-order kinetics and the high sensitivity of the ester bonds to temperature and pH.
- **Connors, K. A., Amidon, G. L., & Stella, V. J. (1986).** *Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists*. Wiley-Interscience.
  - *Key Input:* Provides the Arrhenius parameters and activation energy () ranges for aliphatic esters like SCC (typically **75–95 kJ/mol**).

2. Pharmacopeial Standards (USP)

- **USP Monograph: Succinylcholine Chloride Injection.** *United States Pharmacopeia (Current Revision)*.
  - *Key Input:* Defines the **Succinymonocholine (SMC)** limit (typically **2.0%**) and the pH requirement (**3.0 to 4.5**).
- **USP <1211> Sterilization and Sterility Assurance of Compendial Articles.**
  - *Key Input:* Outlines the calculation requirements and the preference for terminal sterilization over aseptic processing when "technically feasible."

3. Regulatory Guidelines (FDA, EMA, ICH)

- **EMA/CHMP/CVMP/QWP/850731/2017.** "Guideline on the Sterilisation of the Medicinal Product, Active Substance, Excipient and Primary Container."
  - *Key Input:* Contains the **Decision Tree** that mandates terminal sterilization unless "unacceptable degradation" is proven.
- **FDA Guidance for Industry (2004).** "Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice."
  - *Key Input:* Provides the framework for validating aseptic filtration when thermal methods compromise drug integrity.
- **ICH Q3B(R2).** "Impurities in New Drug Products."

- *Key Input:* Sets the thresholds for identification and qualification of degradation products (SMC in this case).

4. Buffering and Catalysis

- **Akers, M. J. (2016).** *Sterile Drug Products: Formulation, Packaging, Manufacturing, and Quality*. CRC Press.
  - *Key Input:* Discusses **General Base Catalysis** and why phosphate/citrate buffers can catalyze the hydrolysis of ester-linked drugs during autoclaving.